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Abstract
Background: The HIV-1 pathogenic factor, Nef, is a multifunctional protein present in the cytosol and on
membranes of infected cells. It has been proposed that a spatial and temporal regulation of the conformation of
Nef sequentially matches Nef’s multiple functions to the process of virion production. Further, it has been
suggested that dimerization is required for multiple Nef activities. A dimerization interface has been proposed
based on intermolecular contacts between Nefs within hexagonal Nef/FynSH3 crystals. The proposed dimerization
interface consists of the hydrophobic B-helix and flanking salt bridges between R105 and D123. Here, we test
whether Nef self-association is mediated by this interface and address the overall significance of oligomerization.
Results: By co-immunoprecipitation assays, we demonstrated that HIV-1Nef exists as monomers and oligomers
with about half of the Nef protomers oligomerized. Nef oligomers were found to be present in the cytosol and on
membranes. Removal of the myristate did not enhance the oligomerization of soluble Nef. Also, SIVNef
oligomerizes despite lacking a dimerization interface functionally homologous to that proposed for HIV-1Nef.
Moreover, HIV-1Nef and SIVNef form hetero-oligomers demonstrating the existence of homologous oligomerization
interfaces that are distinct from that previously proposed (R105-D123). Intracellular cross-linking by formaldehyde
confirmed that SF2Nef dimers are present in intact cells, but surprisingly self-association was dependent on R105,
but not D123. SIVMAC239Nef can be cross-linked at its only cysteine, C55, and SF2Nef is also cross-linked, but at
C206 instead of C55, suggesting that Nefs exhibit multiple dimeric structures. ClusPro dimerization analysis of HIV-
1Nef homodimers and HIV-1Nef/SIVNef heterodimers identified a new potential dimerization interface, including a
dibasic motif at R105-R106 and a six amino acid hydrophobic surface.
Conclusions: We have demonstrated significant levels of intracellular Nef oligomers by immunoprecipitation from
cellular extracts. However, our results are contrary to the identification of salt bridges between R105 and D123 as
necessary for self-association. Importantly, binding between HIV-1Nef and SIVNef demonstrates evolutionary
conservation and therefore significant function(s) for oligomerization. Based on modeling studies of Nef self-
association, we propose a new dimerization interface. Finally, our findings support a stochastic model of Nef
function with a dispersed intracellular distribution of Nef oligomers.
Background
The human immunodeficiency virus type I (HIV-1)
accessory gene product, Nef, is a myristoylated protein
with a decisive role in viral replication and pathogenesis
[1-4]. HIV-1Nef has a canonical length of only 206
amino acids but is functionally complex. Simian immu-
nodeficiency virus (SIV) and human immunodeficiency
v i r u st y p e2( H I V - 2 )N e f sa r ea b o u t5 0a m i n oa c i d s
longer and are also functionally complex [2]. In both
cases functional complexity is reflected in overlapping
effector domains that interact with multiple cellular pro-
teins. These interactions bring about abnormal associa-
tions of host cell proteins that establish a favorable
environment for viral replication [2,5-8]. HIV-1Nef has
a structured core (approximately amino acids 62-147
and 179-200), flexible N- and C- termini (2-61, 201-206)
and an internal flexible loop (148-178). Homology
between HIV-1 and SIV Nefs is largely restricted to the
core region [9]. It has been established that Nef can
exist as a dimer, and to a much lesser extent a trimer,
with the proposed oligomerization domain residing in
the core [10-13].
Several groups have investigated the relationships
between Nef’s cellular localization, oligomerization, and
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any medium, provided the original work is properly cited.its various activities. Specifically, a monomer of Nef has
been proposed to be soluble, compact, and inactive with
the myristate, the N-terminal flexible arm (2-62) and
the internal flexible loop (148-178) all bound to the Nef
core. In this conformation, soluble Nef may be refrac-
tory to oligomerization [14,15]. Support for this model
comes from the report that in vitro myristoylated full-
length Nef is a compact monomer as determined by
analytic gel filtration and ultracentrifugation [15]. Inser-
tion of the myristate alkane chain into the membrane
would remove it from the Nef core, possibly favoring
the dimeric state [15]. Recent studies suggest that an
interaction between positively charged residues within
22 amino acids of the N-terminus and the negatively
charged surface of intracellular membranes act in con-
cert with the myristoyl group to enhance and stabilize
Nef binding to internal membranes [16,17].
The large conformational changes thought to occur
upon Nef binding to membrane are the basis of a tripar-
tite regulatory model for Nef linking conformation,
cellular localization, and function by Arold and Baur
[14]. In this model the initial cytosolic form of Nef is
monomeric, non-functional, and described as “closed.”
Insertion of the myristate group into membrane, and
association of the nearby cluster of arginines (R17, R19,
R21, and R22) with phospholipids, detaches the flexible
N-terminus from the Nef core giving a “semi-open” con-
former. Subsequent extension of the flexible internal
loop (amino acids 148-178) away from the Nef core
gives a fully extended or “open” form of the protein.
These changes could uncover Nef dimerization and
effector domains in conjunction with the localization of
the protein in proximity to its membrane-bound cellular
targets [10,17,18]. The model further proposes that
the sequence of Nef conformations, closed, semi-open,
and open, directs subsets of Nef activities to appear
in a temporal progression from synthesis on cytosolic
ribosomes to membrane attachment and finally co-
internalization with CD4 and other host cell plasma
membrane proteins by the endocytotic machinery. In
this way, Nef would be able to express functions impor-
tant for early HIV-1 replication and then shift to func-
tions appropriate for late HIV-1 replication [14]. Arold
and Baur rejected an alternate model of Nef function in
which discrete conformers of Nef each with a different
set of Nef activities occur randomly and simultaneously.
Reports from Arold and co-workers have also sug-
gested an important role for Nef oligomerization in key
Nef functions including CD4 downregulation, MHCI
downregulation and enhancement of virion infectivity
[10,18]. These authors have described an oligomeriza-
tion surface contained in the second a-helix (aB) of the
Nef core (R105-I114) and 9 amino acids in the trailing
loop. The basis for this proposed dimeric structure
comes from analysis of Nef packing within hexagonal
crystals. D123 is considered to be critical for Nef oligo-
merization since mutating this residue renders the
mutant protein defective for all three of the above Nef
activities [18]. Poe and Smithgall have recently reported
the presence of Nef dimers possibly linked by the 105-
123 dimerization interface, but found Nef dimerization
to be independent of membrane localization [13,19].
Hence, the studies published to date raise a number of
interesting questions regarding the mechanism and pos-
sible significance of Nef oligomerization. Crucial to all
of these considerations is the robustness of the proposed
inhibition of dimerization in the cytosol by the myristate
group. If a significant proportion of oligomeric Nef is
formed in the cytosol and transiently binds to mem-
brane as a dimer; then a stochastic model is favored
over a sequential model.
Here we report that Nef oligomers are present at
levels consistent with functional significance. We also
report evidence that supports an equilibrium model of
different Nef conformations over the previously
described sequential regulation model. For the first time,
the evolutionally diverged SIVNef and HIVNef have
been demonstrated to share at least one oligomerization
interface. Finally, our data indicate the presence of one
or more Nef oligomeric states in addition to the R105-
D123 model previously proposed. Our modeling studies
have suggested a new dimerization interface consistent
with all of our data.
Results
Membrane-bound Nef exists as monomers and dimers
The HIV-1 protein, Nef, is the predominant protein
e a r l yi nH I V - 1r e p l i c a t i o n[ 2 0 ] .N e fh a sb e e ns h o w nt o
be distributed between the cytosolic and membrane-
bound fractions of the cytoplasm [16,21-25]. The initial
questions we addressed were whether or not Nef oligo-
mers are a significant fraction of total membrane-bound
Nef and/or soluble Nef. Previous studies have demon-
strated the presence of Nef dimers in cells by qualitative
assays [12,13]. To determine the extent of Nef dimeriza-
tion in the soluble and membrane fractions of Nef
expressing cells, SF2Nef and NA7Nef were used [26-28].
These well-studied Nefs are highly cross-reactive in our
Western blots (Additional File 1; Figure S1). We used
NA7-HFNef and SF2-HFNef each with a C-terminal tag
containing the HA epitope to be able to resolve these
proteins from untagged Nef [29-31]. In Figure 1A we
demonstrate that the tagged HIV-1 Nefs, SF2-HFNef
and NA7-HFNef, and the untagged NA7Nef are well
expressed in membrane fractions of 293T cells (Input,
lanes 2-4). Note that the tagged proteins are clearly
resolvable from untagged NA7Nef by SDS/PAGE. In
addition, tagged SF2-HFNef is slightly larger than tagged
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Page 2 of 22NA7-HFNef because amino acids 22-25 are repeated in
SF2Nef, making it 4 amino acids longer (Input,l a n e s3
and 4). As expected immunoprecipitation of extract
containing untagged NA7Nef with anti-HA monoclonal
antibody yielded no detectable untagged Nef (Figure 1A,
IP:a-HA, lane 8), but NA7-HFNef and SF2-HFNef could
be readily pulled down (lanes 9 and 10). Co-expression
of NA7-HFNef or SF2-HFNef with untagged NA7Nef
allowed us to document the presence of Nef oligomers
bound to cellular membranes. Western blots of immu-
noprecipitated tagged Nefs with anti-Nef antibody
revealed the association of NA7Nef with SF2-HFNef and
NA7-HFNef (compare lane 9 to 11 and lane 10 to 12,
arrow labeled “U”). In contrast to the bands for tagged
Nefs (T), which represents the total tagged Nef present
(monomers and oligomers are indistinguishable), the
lower molecular weight band (U) only represents the
f r a c t i o no fu n t a g g e dN A 7 N e ft h a ti sa s s o c i a t e dw i t h
tagged NA7-HFNef (lane 11) or SF2-HFNef (lane 12).
Untagged, homodimeric NA7Nef and monomeric
NA7Nef were not immunoprecipitated. Therefore, it is
not possible to estimate the fractional dimerization (FD)
Figure 1 Assays for Nef oligomers by immunoprecipitation. (A) 293T cells were transfected to express untagged NA7Nef (lower molecular
weight band, lane 2) and tagged NA7-HFNef and SF2-HFNef (higher molecular weight bands, lanes 3 and 4) singly and in the combinations of
a tagged Nef with untagged NA7Nef. The membrane-associated protein fraction was prepared and Nef expression was determined by Western
blot analysis (Input, lanes 1-6). Immunoprecipitations were also performed with anti-HA monoclonal antibody and were analyzed by SDS/PAGE
and Western blot analysis (IP: a-HA, lanes 7-12). Antibody for the Western blots was sheep anti-HIV-1Nef. Arrows, untagged NA7Nef (U) present
as hetero-oligomer and total tagged Nef (T). Upper T for SF2-HFNef and lower T for NA7-HFNef. (B) Same as in (A) with the corresponding
cytoplasmic protein fractions. Note that in (A) the slightly lower molecular weight band present in the SF2-HFNef lanes running the same
distance as the NA7-HFNef appears to have been proteolytically modified. In the soluble fractions additional minor proteolytic fragments are
present.
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Page 3 of 22directly. To estimate FD, we considered Nef to be
strictly dimeric since trimers and higher order Nef oli-
gomers are minor species [10-12]. Further, we assumed
a binomial distribution between tagged and untagged
Nefs (Figure 2A). The fractional dimerization (FD) is
ratio of the amount of untagged Nef and tagged Nef
present as dimers divided by the total untagged and
tagged Nef. Densities were determined and corrected by
background subtraction. The corrected densities for the
upper band and the lower band in the immunoprecipi-
tated sample lane (TIP and UIP, respectively) are used as
values that reflect the amount of T and U present in the
immunoprecipitate. The entire amount of tagged Nef
(TIP) in the sample is proportional to the corrected den-
sity of the bands marked T (Figure 1, lanes 11 and 12)
representing immunoprecipitated tagged Nef. The total
amount of untagged Nef cannot be determined directly
from UIP (IP: a-HA, lanes 11 and 12). Instead total
untagged Nef is determined as the amount of tagged
Nef (TIP) times the proportion of untagged Nef to
tagged Nef. This latter ratio is obtained by dividing the
corrected density for U by the corrected density for T
from Input (Input, lanes 5 and 6) to give (UIN/TIN).
Total untagged Nef is proportional to TIP(UIN/TIN).
Therefore, TIP(UIN/TIN)+T IP is proportional to the
total Nef in the sample (denominator in Figure 2B). To
obtain an estimate for total dimeric Nef the corrected
densities of untagged Nef bands (UIP) in the immuno-
precipates is the starting point (Figure 1, IP: a-HA,
lanes 11 and 12). The dominant species present in this
band is the untagged Nef that co-immunoprecipitated
with the tagged Nef, but a minor species may be present
that is a co-migrating proteolytic fragment from the
tagged Nef. This species can be determined from immu-
noprecipitated Nef that is singly expressed (Figure 1,
lanes 9 and 10). The corrected densities of the region of
the blot corresponding to the migration of untagged Nef
(arrow labeled U) in the lanes only expressing tagged
Nef (lanes 9 and 10) were used to correct for the pre-
sence of possible proteolytic fragments in co-immuno-
precipitating bands. Specifically, to obtain UIP for
NA7Nef bound to NA7-HFNef an adjustment for any
proteolytic fragment that could be present was obtained
by subtracting the corrected density at the same level in
lane 9 from “U” in lane 11. Similarly, the UIP for
NA7Nef bound to SF2-HFNef was obtained by subtract-
ing the corrected density in lane 10 from “U” in lane 12.
These adjusted values are proportional to UIP. However,
UIP greatly underestimates total dimeric Nef. Clearly,
there were equal amounts of tagged and untagged Nef
in the immunoprecipitated heterodimers contributing a
two-fold correction in the amount of heterodimeric Nef
(2XUIP). The amount of homodimeric cannot be deter-
mined directly. As seen in (A) a random (binomial)
distribution of U and T will result in equal or nearly
equal amounts of U and T in heterodimers and in
homodimers. Varying the ratio of total U, (UIN), and
total T, (TIN), will shift the equilibrium but the fraction
of U plus T in heterodimers will remain at approxi-
mately 50% of total dimer. In other words, increasing
the level of T over U will give higher levels of homodi-
meric T2 and lower levels of homodimeric U2 (or if U
over T, then U2 >T 2). Therefore, we can conclude that
untagged and tagged Nef present in heterodimers
(2XUIP) is approximately equal to untagged and tagged
Nef in homodimers (2XUIP). This gives total oligomeric
Nef (homodimers and heterodimers): 2XUIP +2 X U IP =
4XUIP (numerator in Figure 2B). The assumption of a
binomial distribution is best made under conditions of
similar levels of tagged and untagged Nef expression.
Experiments in which the UIN/TIN ratios exceeded
3-fold were not presented. This co-immunoprecipitation
assay gives the first estimates of the level of Nef dimeri-
zation in intact cells. However, the complexity of these
calculations and the technical difficulties of quantitating
immunoprecipitations require cautious interpretation
and we do not consider differences in FD of less than
two-fold to be compelling. The FDs of membrane-
bound NA7-HFNef/NA7Nef (Figure 1A, lane 11) and
SF2-HFNef/NA7Nef (Figure 1A, lane 12) were estimated
by the formula in Figure 2B to be 0.52, and 0.48, respec-
tively (Figure 2C).
Nef oligomers are also present in cytosol
The cytosolic fractions corresponding to the membrane-
bound fractions presented in Figure 1A were also ana-
lyzed (Figure 1B). Unexpectedly, Nef oligomers were pre-
sent in the cytosol with FD’s for NA7-HFNef/NA7Nef
and SF2-HF/NA7Nef of 0.35 and 0.23, respectively (Fig-
ure 2C). These values suggested a difference between the
FDs for soluble Nef versus membrane-bound Nef (Figure
2C). Additional experiments confirmed a difference
in FDs for soluble and membrane-bound Nefs (FDsoluble/
FD membrane = 0.52 ± 0.05 with n = 4 and p = 0.015 by
paired t-test). This 50% lower FD for soluble Nef is quali-
tatively consistent with the suggestion that the myristate
group interacts with the Nef core in soluble Nef and
diminishes dimerization [14,15]. However, the fact that
this is a partial effect means alternative mechanisms may
account for the result.
The role of the N-terminal myristate in oligomerization
Our observation of significant levels of Nef oligomers in
the soluble protein fractions suggested that the proposed
inhibition of Nef dimerization by its myristate group
was weak at best. Nonetheless, if the observed 50%
reduction in the fraction of Nef oligomers in the cytosol
compared to membrane-bound Nef was the result of
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Page 4 of 22Figure 2 Estimation of Fractional Dimerization. (A) There are three forms of Nef dimers possible- homodimers of tagged Nefs (T2)a n d
untagged (U2) Nefs and heterodimers (TU, UT). We have assumed a random assortment of tagged and untagged Nefs with a binomial
distribution (1:2:1) of dimeric forms. (B) The equation for the fractional dimerization (FD). (C) The corrected densities (divided by 1000),
determined by ImageJ, for the experiment presented in Figure 1A, B were used to calculate FD’s. (D) The corrected densities/1000 determined
by ImageJ for the experiment presented in Figure 3A, B and the calculated FD’s are given. (E) The corrected densities/1000 for the experiment
in Figure 4A and the FD are presented.
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should give a higher fraction of Nef dimers in the cyto-
sol than that observed for the parental SF2Nef [14,15].
The capacity of tagged SF2-HFNef and the myristoyla-
tion-defective SF2-HFNefG2A to oligomerize with
untagged SF2Nef is shown in Figure 3. It has been
previously shown that the myristoylation defective Nef
associates with cellular membranes, though the majority
of this protein is soluble (Additional File 2; Figure S2,
Right and [16]). We observed in Figure 3A, lane 12 that
myristoylation-defective tagged Nef from the membrane
fraction associates with untagged SF2Nef, and that this
Figure 3 Myristoylation defective Nef does not exhibit enhanced oligomerization. (A, B) The abilities of untagged SF2Nef to associate with
tagged SF2-HFNef or SF2-HFNefG2A in membrane and soluble fractions were compared using the immunoprecipitation assay. The co-
immunoprecipitated SF2Nef is indicated by an arrow marked “U” to the right of lane 12 (lanes 11 and 12). The total tagged Nef is indicated by
an arrow marked ‘’T’’. (A), Membrane-bound Nef. (B), Cytosolic Nef. (C) Data from additional experiments were combined to assess the FDs for
the binding of SF2Nef to SF2-HFNef and SF2-HFNefG2A. Analysis was performed as in Figure 2.
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tagged and untagged Nefs (lane 11). For soluble
Nef there was also no apparent enhancement of oligo-
merization as a result of the G2A mutation (Figure 3B,
lanes 11 and 12). The FDs for this experiment are given
in Figure 2D. The membrane-bound and soluble
SF2NefG2A dimerization experiments were repeated
a n dF D sd e t e r m i n e d( F i g u r e3 C ) .N od i f f e r e n c ew a s
observed for FDs of soluble SF2Nef and SF2NefG2A
while a small reduction was observed in FDs for mem-
brane-bound SF2NefG2A compared to SF2Nef (FDG2A/
FDSF2 = 0.70 ± 0.05 with n = 3a nd p = 0.028 by paired
t-test). These combined results suggest that oligomeriza-
tion is a constitutive property of Nef with little or no
impact attributable to the presence of the myristate
group. In the absence of compelling evidence that
removal of the myristate group on Nef enhances dimeri-
zation, a possible explanation for the two fold higher FD
for membrane-bound Nef versus soluble Nef could be
that the dimeric entity may preferentially bind mem-
brane compared to monomer because it has two mem-
brane association sites.
SIVMAC239Nef forms oligomers
The SIVMAC239Nef protein is derived from a proviral
molecular clone encoding a virus that is highly pathogenic
in rhesus macaques [3]. It has all the major activities of
SF2Nef in human cells, despite only 43% identity between
the two proteins [2]. Interestingly, Arold et al. have argued
that non-conserved residues in SIV and HIV-2 Nefs rela-
tive to HIV-1 Nefs (115Y in HIV-1Nef to D or E in SIV-
Nef and 116 H in HIV-1Nef to R in SIVNef) would lead to
burying charged residues in the hydrophobic core of the
proposed dimerization domain of aBh e l i x[ 1 0 ] .T h i s
sequence difference between SIV and HIV-1 Nefs sug-
gested that SIV Nefs would not oligomerize or do so by a
different mechanism to HIV-1Nefs. In an analogous
experiment to Figure 1 we asked the question if tagged
SIVMAC239-HFNef associates with untagged SIVMAC239Nef
( F i g u r e4 A ) .W ep r e p a r e dm e m b r a n ef r a c t i o n sa n da n a -
lyzed Nef expression by Western blot analysis. We also
performed immunoprecipitations with anti-HA antibody.
SIVMAC239Nef can be resolved from SIVMAC239-HFNef by
SDS/PAGE (Figure 4A, Input, lanes 2-4) and anti-HA anti-
body failed to immunoprecipitate SIVMAC239Nef (Figure 4A,
IP: a-HA, lane 6). However, when SIVMAC239Nef is
co-expressed with SIVMAC239-HFNef, followed by immu-
noprecipitation with anti-HA antibody, untagged SIV-
MAC239Nef is brought down in association with tagged
SIVMAC239-HFNef (lane 8, lower arrow). The relative
intensities of the T and U bands correspond to FD = 0.37
(Figure 2E). This striking observation demonstrated the
existence of SIVMAC239Nef oligomerization that is unre-
lated to the previously proposed dimerization interface
[10,18]. If SIVNef oligomerization is by a different
mechanism to HIV-1Nef then one would not expect the
two proteins to associate. In a preliminary experiment we
observed that following co-expression SIVMAC239-HFNef
did indeed pull down SF2Nef which is an HIV-1Nef
(not shown). Accordingly, we have investigated the het-
erologous association of SF2Nef and SIVMAC239Nef
without tags that were specifically immunoprecipitated
with non-crossreacting antibodies. SF2Nef and SIV-
MAC239Nef were expressed either singly or together.
Membrane and cytosolic protein fractions were pre-
pared and analyzed in Figure 4B and 4C, respectively.
The levels of the two Nef proteins are shown in Figure
4B and 4CInput. The analyses of the two immunopreci-
pitations, with either anti-HIVNef or anti-SIV Nef anti-
sera, are presented in Figure 4B and 4C (IP: a-HIV Nef
and IP: a-SIV Nef). The anti-HIVNef antiserum did not
precipitate SIVMAC239Nef (Figures 4B and 4C, lane 7,
lower panels) and the anti-SIVNef antiserum did not
precipitate SF2Nef (Figures 4B and 4C, lane 10, upper
panels). Immunoprecipitations of extracts containing
the co-expressed Nefs brought down the non-reactive
protein, demonstrating an association between HIVNef
and SIVNef (Figure 4B and 4C, IP: a-HIV Nef,c o m p a r e
in the lower panels, lanes 7 and 8; and IP: a-SIV Nef,
compare in the upper panels, lanes 10 and 12). The
observed heterologous association between SF2Nef and
SIVMAC239Nef implies there are homologous dimeriza-
tion interfaces present in these Nefs that are distinct
from the previously proposed dimerization interface
(R105-D123).
Nef dimers in intact cells
We next considered the question of Nef self-association
in intact cells. Formaldehyde readily penetrates the cell
surface membrane and cross-links intracellular proteins
at lysines [32]. First, we optimized the detection of Nef
oligomers in intact cells by treating SF2Nef-expressing
293T cells with increasing levels of formaldehyde fol-
lowed by analysis of cell-free lysates by SDS/PAGE and
Western blot. The optimal concentration of formalde-
hyde for cross-linking Nef dimers was determined to be
0.5% (not shown). In Figure 5A we demonstrate that
SF2Nef can be cross-linked to yield a single major spe-
cies under these conditions. Our results are similar to
the findings of Kienzle et al. with HIV-1LAI Nef cross-
linked with bis(sulfosuccinimidyl)suberate in intact
insect cells [12]. Interestingly, under the same experi-
mental conditions SIVMAC239Nef produced two major
cross-linked forms. Whether both of these forms repre-
sent cross-linked SIVMAC239Nef dimers at different
lysine residues or whether one is dimeric Nef and the
other the result of cross-linking to a cellular protein is
not known (See Discussion).
Kwak et al. Retrovirology 2010, 7:77
http://www.retrovirology.com/content/7/1/77
Page 7 of 22Figure 4 SIVMAC239Nef oligomerizes and also forms heterologous oligomers with SF2Nef. (A) 293T cells were transfected to express
tagged SIVMAC239-HFNef and untagged SIVMAC239Nef, singly and in combination. Membrane protein fractions were prepared and Nef expression
was determined by Western blot analysis (Input). Immunoprecipitations were performed with anti-HA monoclonal antibody and the
immunoprecipitates analyzed by SDS/PAGE followed by Western blotting with monoclonal anti-SIV antibody (IP:a-HA). Arrows, total tagged Nef
(T) and untagged Nef bound to tagged Nef (U). (B and C) 293T cells were transfected to express SF2Nef and SIVMAC239Nef singly and in
combination. Membrane (B) and soluble (C) protein fractions were prepared and Nef expression determined by Western blot analysis with anti-
HIVNef monoclonal antibody (Input, upper panels) and anti-SIVNef monoclonal antibody (Input, lower panels). The membrane and soluble
fractions were also immunoprecipitated with polyclonal anti-HIV-1Nef (IP: a-HIV-1Nef) and polyclonal anti-SIVNef (IP: a-SIV Nef). The
immunoprecipitates were analyzed by Western blot with monoclonal anti-HIV Nef (upper panels) and monoclonal anti-SIVNef (lower panels).
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cross-linking with formaldehyde are present at 15% or
less of the total Nef. The likely explanation is that much
of the intracellular dimer is either not cross-linked or
non-specifically cross-linked. Concentrations of formal-
dehyde higher than 0.5% resulted in weaker dimer
bands due to non-specific cross-linking (not shown).
Therefore, it is clear that the results of the formaldehyde
Figure 5 Cross-linking Nef dimers in intact cells with formaldehyde. (A) 293T cells were transfected to express SF2-HFNef or SIVMAC239-
HFNef. Intact cells were incubated with 0.5% formaldehyde for 10 minutes at room temperature. Clarified whole cell lysates were prepared and
Nef detected by Western blot analysis. (-), incubation without formaldehyde. (+), incubation with formaldehyde. Arrows, cross-linked Nef dimers.
(B) Assay of intracellular oligomerization with NA7Nef/SF2Nef chimeras. The chimeric expression vectors were made by substituting coding
sequence for amino acids 24-200 SF2Nef into NA7Nef and the same coding sequence for NA7Nef into SF2Nef. Oligomerization was assayed by
formaldehyde cross-linking in intact cells as in (A). NA7(SF2)Nef, NA7Nef with coding sequence for amino acids 24-200 replaced by coding
sequence for the same amino acids from SF2Nef. SF2(NA7)Nef, the reciprocal construct as NA7(SF2)Nef. (-), incubation without formaldehyde; (+),
incubation with formaldehyde. Arrow, cross-linked Nef dimer. (C), The ability of SF2NefG2A to associate with itself was compared to SF2Nef by
the formaldehyde cross-linking assay with intact cells. Arrow to the right of lane 4 indicates cross-linked Nef (lanes 2 and 4). (+), Cells incubated
with 0.5% formaldehyde for 10 minutes at room temperature. (-), Cells incubated in the absence of formaldehyde.
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Page 9 of 22cross-linking assay are not quantitative and may not be
comparable to the immunoprecipitation assay. To test if
the two assays yield similar results we took advantage of
a tendency we noted in the immunoprecipitation assay
f o r2 - f o l dh i g h e rF D ’s for oligomers composed of
SF2Nef and SF2-HFNef relative to complexes containing
NA7Nef or NA7-HFNef with each other or in hetero-
dimeric combinations with SF2-HFNef or SF2Nef,
respectively. To carefully compare the strength of self-
interactions between SF2Nef and NA7Nef, we deter-
mined the FD’s for the four possible combinations of
SF2-HFNef with SF2Nef or NA7Nef, and NA7-HFNef
with SF2Nef or NA7Nef by the immunoprecipitation
assay of membrane-bound Nef (not shown). These FDs
confirmed the initial observation. Combining all our
relevant data, we found the FD for SF2Nef homodimers
to be 0.71 ± 0.10 (n = 5) and for SF2Nef/NA7Nef het-
erodimers plus NA7Nef homodimers to be 0.30 ± 0.09
(n = 5). This difference was statistically significant (p =
0.032 by Mann Whitney test), and suggested that
NA7Nef lacks one or more structural features present in
the SF2Nef that stabilize dimerization. The observed dif-
ference in FDs allowed us to address whether the for-
maldehyde cross-linking assay was detecting the same
oligomers as the immunoprecipitation assay. In that
case there should also be a reduction in NA7Nef com-
plexes relative to SF2Nef by formaldehyde cross-linking.
The results in Figure 5B, lanes 3 and 5, demonstrate
that this is in fact the case. Taking advantage of our
finding we swapped the core domains of SF2Nef and
NA7Nef to determine if the core sequences accounted
for the observed differences in self-association. In Figure
5B, lanes 7 and 9 we observed that the NA7(SF2)Nef
chimera with the SF2Nef core exhibited greater cross-
linking than the SF2(NA7)Nef chimera with the NA7Nef
core. These results strongly suggest that the formalde-
hyde cross-linking assay and the immunoprecipitation
assay are detecting the same Nef oligomers and that
oligomerization is dependent on core sequences.
The important finding that the immunoprecipitation
assay and the intracellular cross-linking assay give simi-
l a rr e s u l t sf o rS F 2 N e fa n dN A 7Nef self-association led
us to determine if the results of Figure 3 would also be
confirmed. In Figure 5C we observed that SF2NefG2A
did not exhibit enhanced dimerization by the formalde-
hyde cross-linking assay consistent with the results of
the immunoprecipitation assay.
Can Nef dimers be cross-linked at cysteines?
It has been reported that air oxidation of HIV-2NIH-Z
Nef and HIV-1LAI Nef results in the formation of cross-
linked dimers [11,12]. We have confirmed these obser-
vations with SIVMAC239Nef and SF2Nef (Additional File 3;
Figure S3). The observed dimers were formed by
intermolecular cystine bonds, as demonstrated by their
elimination in the presence of high concentrations of
2-mercaptoethanol (Additional File 3; Figure S3, lanes 1,
2, and 9). The S-S bond formation in SIVMAC239Nef
dimers must occur at cysteine 55, since it is the only
cysteine. However, both HIV-1LAINef and SF2Nef have
cysteines at 55, 142, and 206- the C-terminal amino acid.
To determine which of these cysteines are involved in
cross-linking, we mutated each of the cysteines,
SF2NefC55S, SF2NefC142S, and SF2Nef with C206
deleted (SF2NefC206X). Clarified cell-free extracts con-
taining these Nefs were cross-linked with BM[PEG]3.I n
Figure 6A, left, SF2Nef and SF2NefC55S exhibited cross-
linking, but SF2NefC206X did not. BM[PEG]3 cross-
linked SIVMAC239Nef at C55 (Figure 6A, right). The
d i v e r g e n tr e s u l tt h a tS I V MAC239Nef is cross-linked at
C55, but SF2Nef is not, suggests a dimeric interface pre-
sent in SIVMAC239N e ft h a ti sa b s e n ti nS F 2 N e f .T h i s
dimeric interface unique to SIVMAC239Nef would be sepa-
rate from the dimerization interface responsible for het-
erologous association.
In Figure 6B, top, we checked the impact of C55S
and C206X on the ability of SF2Nef to downregulate
CD4 downregulation and MHCI downregulation; both
mutants were found to be functional. Neither mutation
reduced the level of Nef expression relative to SF2Nef
(Figure 6B, bottom). In contrast, SF2NefC142S was sig-
nificantly less stable than the other two cysteine mutants
(not shown), confirming previous reports [33,34]. This
mutant was partially defective for MHCI downregulation
but fully functional for CD4 downregulation. Since
MHCI downregulation is more sensitive to reduced
levels of Nef expression than CD4 downregulation, this
result is expected [31]. Residue 142 is completely buried
in the hydrophobic core of Nef and unlikely to be
involved in intermolecular S-S bonds between native
Nefs [14].
On the basis of these cross-linking experiments, it
appears that SF2Nef exhibits a dimeric structure that
brings C-terminal regions into proximity. Inspection of
space filling models of Nef dimers associated at the pre-
viously proposed R105-D123 interface shows the two
C-terminal cysteines to be distant from each other (not
shown). A second Nef/Nef interaction surface found in
cubic crystals of Nef extends from R188 to E197 plus
F139 but does not include C206 [10]. This surface is
viewed by Arold et al. as a biologically irrelevant result
of crystal packing [10]. However, it is clear from inspec-
tion of Nef crystal structures that if Nef self-association
was mediated by this interface in the C-terminal
domain, then cross-linking of C206 by the BM[PEG]3
reagent would be possible (not shown). These considera-
tions suggest that the cysteine cross-linking result in
Figure 6A may reflect proximity of C-terminal cysteines
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Page 10 of 22Figure 6 Cross-linking Nefs dimers with BM[PEG]3. (A) 293T cells were transfected to express SF2Nef, SF2NefC55S and SF2NefC206X (left,
lanes 1-10), and SIVMAC239Nef (right, lanes 11 and 12). Clarified whole cell Iysates were incubated with BM[PEG]3. Nef was then detected by
Western blot analysis. (-), clarified whole cell Iysates incubated in the absence of BM[PEG]3 for 1 hour at room temperature (lanes 1-5 and 11). (+),
clarified whole cell Iysates incubated in the presence of 0.5 mM BM[PEG]3 for 1 hour at room temperature (lanes 6-10 and 12). The presence of
crosslinked Nefs was detected by Western Blot analysis. NT, 293T cells not transfected. (B) SF2Nef, SF2C55S, and SF2C206X were assayed for CD4
downregulation and MHCI downregulation in transduced CEM cells (top). The level of expression of SF2Nef, SF2NefC55S and SF2NefC206X in CEM
cells was determined by Western blot analysis (bottom). (C) Lysates from transfected 293T cells expressing SF2NefC206X, SF2NefC55S, and SF2Nef
were cross-linked by 0.5% formaldehyde.
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Page 11 of 22in the SF2Nef BM[PEG]3 cross-linked dimer, but not a
structural role in dimerization per se. To test this con-
clusion we cross-linked SF2Nef, SF2NefC55S, and
SF2NefC206X with formaldehyde and found no impact
of cysteine mutations on dimerization (Figure 6C).
Therefore, we interpret our cysteine cross-linking results
as reflecting the location of an interaction interface but
not defining C206 as a critical structural element for
dimerization. It is interesting to note in this regard that
15% of subtype B Nefs have no C-terminal cysteine but
a termination codon instead (TGY to TGA).
Salt bridges flanking the aB helix are not necessary for
oligomerization
I th a sb e e np r o p o s e dt h a tR 1 0 5 forms salt bridges with
D123 on the flanks of the amphipathic aB helix, and
that mutation of D123 disrupts oligomerization [10,18].
Several groups have reported multiple functional conse-
quences of mutating D123, including CD4 downregula-
tion, MHCI downregulation, and enhancement of virion
infectivity. The multiple defective phenotype of D123
mutants has been attributed to disruption of Nef dimeri-
zation [18]. The conservative mutation D123E gives the
same defective phenotype as non-conservative muta-
tions, and has also been found to enhance p21-activated
protein kinase 2 (PAK2) activation relative to unmodi-
fied SF2Nef [8]. The significant impacts on four separate
Nef activities define a distinctly complex D123 mutant
phenotype [8,14,18,28,35,36]. However, the fact that
aspartate replaced by the isoelectric glutamate generates
the equivalent phenotype as non-conservative mutations
suggests that the isoelectric mutation involves disruption
of precise structural considerations beyond mere charge
interactions. A phenotypic impact as a result of mutat-
ing D123 to glutamate is consistent with its extreme
conservation (>99%). In contrast, HIV-1 subtype B Nefs
are weakly conserved at position 105 with 71% lysine,
22% arginine, and 6% glutamine [8].
The impact of mutating R105 and D123 on the level of
Nef dimers in intact cells is presented in Figure 7A. We
initially used the replacement mutations R105D, D123R,
and R105D/D123R. We observed that SF2NefR105D is
defective in dimerization consistent with the salt bridge
model but SF2NefD123R gave no effect on dimerization
(Figure 7A). The double mutation was nearly wild type
for dimerization. To assess this unexpected result that
R105D was defective for dimerization but D123R was
not, we investigated the functional impacts of these
mutations (Figure 7B, left and middle). SF2NefD123R is
fully defective for CD4 downregulation and MHCI down-
regulation but enhanced for PAK2 activation as pre-
viously reported for SF2NefD123E [8]. Thus, the drastic
mutation of D123R gave the equivalent phenotype as the
conservative mutation D123E [8]. The partially functional
defects previously reported for R105A were also observed
for the charge reversal mutation R105D (Figure 7B, left,
middle, and [8]). The double mutation SF2NefR105D/
D123R that could in theory interact with itself failed to
restore Nef function in these assays (Figure 7B, left and
middle). Instead the double mutant gave the complete
D123 mutant phenotype of no CD4 or MHCI downregu-
lation, but strong activation of PAK2. None of the muta-
tions resulted in an unstable protein (Figure 7B, right).
These observations clearly dissociate the D123 and R105
mutant phenotypes. The combined import of the present
investigation with the previously published functional
results of O’Neill, et al. [8] demonstrates that loss of a
salt bridge does not account for the distinct, multi-func-
tional defects that result from mutating D123 or R105.
The replacement mutations for R105 and D123 were
designed to test the proposal that R105 and D123 were
components of a critical salt bridge within a functionally
significant dimerization domain. Since our results failed
to verify the salt bridge model, we considered alterna-
tive explanations for the roles of R105 and D123. One
explanation is that mutation of D123 locks Nef into a
conformation that is competent for dimerization, but
nonetheless different from the conformation of the bulk
o fw i l dt y p eS F 2 N e f .T h i sh y p o t h e s i si sb a s e do nt h e
fact that adding the R105D mutation to give the double
mutant has little effect on dimerization per se, and
no effect on the functional properties of Nef mutated
at D123.
We next considered a role for R105 in dimerization of
wild type Nef distinct from D123. Also, of potential
interest was the adjacent R106. Unlike R105 R106 is
highly conserved (99%). The isoelectric mutation of
R106 to lysine, in analogy to D123E, gives a complex
phenotype that is quite different from D123E. As pre-
viously reported, R106K is highly defective for MHCI
downregulation, partially defective for PAK2 activation
but functional for CD4 downregulation and enhance-
ment of infectivity. R106A has a more drastic pheno-
type- defective for MHCI downregulation, fully defective
for PAK2 activation, partially defective for CD4 downre-
gulation, and fully defective for enhancement of infectiv-
ity. R106L like R106A is fully defective for MHCI
downregulation and PAK2 activation but also fully
defective for CD4 downregulation [8]. To try and dis-
cern if dimerization possibly plays a role in these com-
plex phenotypes we compared the effects of mutating
R105 and R106 (R106A, R105A, and R105D) to mutat-
ing D123 (D123R and R105D/D123R). In Figure 7C the
R105A and the R106A mutant proteins had reduced
levels of Nef dimerization, though not to the extent of
the reduction observed for R105D. This suggests that
the region of Nef containing R105 and R106 is signifi-
cant for dimerization and that having the negatively
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Page 12 of 22Figure 7 R105 and R106 are critical for Nef oligomerization. (A), 293T cells were transfected to express SF2-HFNef (WT), SF2-HFNefR105D
(R105D), SF2-HFNefD123R (D123R), and SF2-HFNefR105D/D123R (R105D/D123R). The presence of Nef dimers was detected by treatment of intact
cells with 0.5% formaldehyde (+). No formaldehyde (-). (B) Transduced CEM cells expressing SF2Nef, SF2NefR105A, SF2NefD123E, SF2NefR105D,
SF2NefD123R, or SF2NefR105D/D123R plus the vector (LXSN) positive control were assayed for CD4 and MHCI cell surface expression by flow
cytometry analysis (left) , PAK2 activation (middle), and level of Nef expression by Western blot analysis (right). (C) Role of R105 and R106 in
dimerization was investigated as in (A). SF2-HFNefR105A (R105A), SF2-HFNefR106A (R106A).
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Page 13 of 22charged D at position 105 may disrupt the normal inter-
actions of the positively charged R106. It is important to
note that 93% of Nefs are lysine or arginine at residue
105 and 99% arginine at 106 suggesting that a +2 charge
for these two adjacent residues is necessary for optimal
function.
Modeling Nef dimerization
To gain further insight into potential Nef dimerization
interfaces, we employed ClusPro 2.0 http://cluspro.bu.
edu for a rigid body docking analysis of Nef. The struc-
ture of the monomer used in the ClusPro search, was
extracted from the hexagonal crystal structure of Nef
(PDB ID 1AVZ, Chain A). For our initial ClusPro analy-
sis, we used the same structure of the Nef monomer as
both receptor and ligand. The Nef-Nef interface in the
crystal structure providing our search model is the basis
for the proposal that the R105-D123 interaction forms a
critical component of the dimerization interface. Thus,
the Nef structure employed in the ClusPro analysis has
R105 and D123 side chains in positions appropriate and
optimal for formation of the proposed dimerization
interface involving the R105-D123 salt bridge. We chose
the 10 most strongly interacting models of dimeric Nef
structures for analysis. Seven of the structures involved
at least part of the aB helix hydrophobic domain. Inter-
estingly, none of the 10 models included the R105/D123
salt bridge that was evident in the crystal structure.
We developed three criteria to select the model most
likely to be of biological significance from among the
seven potential models. First, a model must involve
R105 and R106, but exclude D123. The second criterion
was that that the model should involve highly conserved
residues within Nef. The third criterion required that
the potential interface found in the HIV-1Nef homodi-
mer ClusPro analysis also be found in a second ClusPro
analysis of the HIV-1Nef and SIVMAC239Nef heterodi-
mer. This third criterion became possible with the pub-
lication of the structure of the SIVMAC239Nef core [37].
We have shown here that SF2Nef associates with both
SIVMAC239Nef and itself, presumably using homologous
interfaces. This implies that there should be a similar
model for both the homo- and heterodimer. In the Clu-
sPro analysis to search for heterodimer interfaces, SIV-
MAC239Nef was the ligand and HIV-1Nef was the
receptor. As with the HIV-1Nef/HIV-1Nef analysis, the
ten most strongly interacting models were inspected.
Comparisons between the homodimer and the heterodi-
mer models gave a pair which fit the above three critera
(Figure 8A). The positions of the ligand HIV-1Nef, (Fig-
ure 8A; cartoon- left, light orange) and ligand SIV-
MAC239Nef (Figure 8A; cartoon: right, cyan) relative to
the receptor HIV-1Nef (cartoon plus transparent sur-
face: magenta) are strikingly similar. None of the other
homodimer models matched any of the heterodimer
models to give a strikingly matched pair.
For the Nef homodimer (Figure 8B, light orange back-
ground) the residues that interact between the Nef
monomers are presented. For example, ligand R106
interacts with L100, R106, I109, and W183 in b5( 8 B ;
light orange background). In total, the ligand HIV-1Nef
has 17 residues that interact with the receptor Nef, 14
of which react with the same side chains in receptor
N e fa sr e s i d u e si nS I V MAC239Nef (identical interactions
shown in bold, Figure 8B). In the homodimer receptor,
11 residues interact with the ligand with ten of these
residues matching ligand residues in SIVMAC239Nef
residues.
In the HIV-1Nef/SIVMAC239Nef heterodimer (Figure 8B,
light blue background) the ligand SIVMAC239Nef has 21
residues that interact with the receptor Nef compared to
17 for the HIV-1Nef ligand. Three of the four extra resi-
dues (S201, Q202, and W203) are from the C-terminal
portion of the internal loop that is present in SIVMAC239-
Nef core construct that is deleted in the HIV-1 Nef core.
In the heterodimer receptor, 18 residues interact with the
ligand SIVMAC239Nef compared to 11 for the HIV-1Nef
homodimer receptor. The seven extra amino acids mostly
interact with residues in the SIVMAC239Nef ligand that
are not present in the Nef core structure, accounting for
12 of 16 interactions. The extra SIVMAC239Nef residues
are in internal loop or the N-terminal side of PQVPLR
near the beginning of the Nef core region. Potentially,
the agreement between heterodimer and homodimer
would be even greater if the Nef structure contained the
extra residues.
An interesting feature of both models is the insertion of
R105 of the receptor into a pocket in the ligand formed by
C-terminal end of the aA helix and the trailing loop (Fig-
ure 8A, insets). The importance of R105 is emphasized by
the fact that R105 in both receptors and R105/R137 in the
ligands contribute to the interface (Figure 8B). There are 7
additional residues that are also part of the dimer interface
in all four Nefs in the two models. In HIV-Nef these are
located just prior to aB (L100, I101), are contained in aB
(R105, R106, I109, L112, W113), or just past the C-termi-
nus of aB (H116). These eight residues overlap with pre-
viously proposed Nef interaction interfaces [10,35]. These
are the R105-D123 crystal interface (Figure 9A, left- Red
and Orange), and the thioesterase II interacting region
which is contained within R105-D123 (Figure 9A, left,
Orange). The SIVNef/HIV-1Nef binding interface pro-
posed in this report is indicated in Figure 9B, left, Cyan.
Comparing Figures 9A, left and 9B, left demonstrates the
substantial overlap between the proposed SIVNef/HIVNef
interface and the previously proposed interfaces. In Figure
9B, right, one of the highly conserved regions (region 1)
between SIVNef and HIV-1Nef (Seafoam Green)i s
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Page 14 of 22Figure 8 Three dimensional models of HIV-1 Nef homodimer and HIV-1 Nef/SIVMAC239Nef heterodimer. (A) Three dimensional
representation of HIV-1Nef interacting with itself (left) and SIVMAC239Nef (right), identified by rigid body docking using ClusPro. In both docking
experiments, HIV-1Nef (PDB 1AVZ, Chain A) was entered as receptor (left and right- magenta cartoon and transparent surface). In the
homodimerization docking, the same Nef was entered as ligand (left, light orange cartoon). In the heterodimerization docking SIVMAC239Nef (PDB
3IK5, Chain A) was entered as ligand (right, cyan cartoon). The models shown here represent the two complexes generated by ClusPro in which
SIVMAC239Nef and HIV-1Nef interact with the receptor HIV-1Nef in a nearly identical manner. R105 and R106 for HIV-1Nef and SIVMAC239Nef R137
and R138 are represented as ball and stick. Inserts show receptor R105 inserted into a pocket of ligand Nef. (B) Residues interacting in the
interface of the HIV-1Nef homodimer, and residues interacting in the interface of the HIV-1Nef/SIVMAC239Nef heterodimer presented in (A). The
three rows of amino acids from F90 to W183 for HIV-1Nef and F122 to W213 for SIVMAC239Nef contain all of the residues present at the two
dimer interfaces. In the case of SIVMAC239Nef, the residues are orthologs of HIV-1Nef residues. In the heterodimer section (lower half), the HIV-
1Nef and SIVMAC239Nef residues that are identical between the two proteins are shaded yellow. Under each boxed residue are the residue or
residues that interact with the designated amino acid. Identical interactions between the homodimer and the heterodimer are in bold font.
Amino acids S201, Q202, and W203 in SIVMAC239Nef correspond to HIV-1Nef internal loop amino acids 171-173 which are deleted in the HIV-1Nef
core construct. The extents of conservation at each amino acid position presented in (B) for HIV-1 subtype B Nefs are: F90, 99%; L91, 98%; K92,
98% for R or K; K94, 95%; G95, 99%; G96, 99%; L97, 99%; G99, 99%; L100, 99% for L, I, or M; I101, 98% for I or V; S103, 98%; R105, 99% for K, R, or
Q; R106, 99%; D108, 99% for D or E; I109, 99%; L112, 99%; W113, 99%; Y115, 97%; H116, 99% for H or N; T117, 99%; F121, 99%; P122, 99%; W183,
99%. All positions with multiple residues only have amino acids that have positive BLOSUM62 scores (53).
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Page 15 of 22Figure 9 Three dimensional representations of the functional regions of Nef that interact with host cell proteins or represent putative
dimerization domains. (A) left, Red and Orange, aB and flanking loop amino acids of the Nef/Nef interface in hexagonal crystals of PDB 1AVZ
(amino acids D108, L112, Y115, H116, F121, P122, D123); Orange, residues that interact with human thioesterase (amino acids D108, L112, F121,
P122, D123); Yellow, PQVPLR in the proline helix of the Nef SH3 binding domain (amino acids 72-77); Blue, residues that interact with the
cytoplasmic tail of CD4 (amino acids W57, L58, E59, G95, L97, R106, L110); right, Image is rotated 180 degrees. Lilac and Magenta, C-terminal Nef/
Nef interface seen in cubic crystals of PDB 1AVV (amino acids F139, R188, F191, H192, H193, R196, E197); Magenta and Purple, residues known to
play a role in PAK-2 activation (amino acids H89, S187, R188, F191); Green, residues that form a hydrophobic pocket interacting with Ile96 of the
RT loop of the Hck SH3 domain (amino acids L87, F90, W113, I114). (B) left, Cyan, critical residues identified in the protein-protein docking
experiments, showcased in Figure 8. Only residues that interact in both the receptor and ligand in both the homodimeric and heterodimeric
models are indicated (amino acids L100, I101, R105, R106, I109, L112, W113, H116); blue violet, one of two regions (region 2) of HIV-1Nef that is
highly conserved in SIV Nef with 22 out of 27 identities (amino acids 122 to 148). right, Seafoam green, second of two regions (region 1) of HIV-1
Nef that is highly conserved in SIV Nef with 11 out of 12 identities (amino acids 88-99).
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Page 16 of 22indicated. This region is adjacent to our proposed SIVNef/
HIV-1Nef interaction surface and interacts extensively
with R105 and R106 of the ligand in the two ClusPro
models. Additional reported interfaces are shown in
Figure 9A, right [8,10,38,39]. Not shown are additional
interactions of Nef’s flexible internal loop with AP-1 and
AP-2 and the N-terminal arm with cellular membranes
and the cytoplasmic tail of MHCI [6,7,16,17,40,41]. The
close packing of overlapping domains with the potential
for protein/protein interactions creates a remarkable
structure/function complexity. Ternary complexes and
allostery have recently been proposed for Nef and may be
common aspects of this protein’s ability to enhance viral
fitness [40-42]. Our results demonstrate that oligomeriza-
tion is a third significant mechanism for achieving unpre-
cedented structure/function complexity.
Discussion
Prior to the present report, the extent of Nef oligomeriza-
tion was not known nor had the regulatory model of
Arold and Baur been directly tested [14]. Poe and Smith-
gall reported the presence of Nef dimers in intact cells by
bimolecular fluoresecence complementation but the frac-
tional dimerization was not assessed [13]. To investigate
Nef self-association, we have employed two assays. First,
the immunoprecipitation assay which utilizes a tagged
Nef and an untagged Nef. The tag allowed us to differ-
entiate between the two otherwise identical Nefs immu-
nologically and by different mobilities on SDS/PAGE
electrophoresis. This approach allowed us to demon-
strate, for the first time, that Nef oligomers are distribu-
ted between the membrane and cytosol compartments of
the cell. We placed the tag at the C-terminus to preserve
Nef myristoylation. The results from this assay were
compared to intracellular cross-linking by formaldehyde.
We have also demonstrated for the first time that SF2Nef
can be cross-linked by BM[PEG]3. This cysteine reactive
agent cross-linked only at C206 and provided new infor-
mation of a structural nature regarding the location of a
Nef dimerization interface. With these new approaches
we have investigated previously unaddressed questions
regarding Nef oligomerization, and identified R105 and
R106 as important constituents of a dimeric interface.
What is the proportion of Nef that is oligomeric in cells?
With the immunoprecipitation assay we found approxi-
mately two thirds of membrane-bound SF2Nef is oligo-
merized. Lower levels of oligomerization by half were
observed for membrane-bound NA7Nef and SIVMAC239-
Nef. All three of these Nefs are highly functional, well-
studied alleles [2,26-28,43] though NA7Nef exhibits
weak PAK2 activation relative to SF2Nef [31]. In the
case of NA7Nef and SF2Nef, the structured cores
accounted for the allelic variation.
Is Nef oligomerization inhibited by the N-terminal
myristate group?
To assess whether or not Nef oligomerization is regu-
lated by membrane association, we determined the frac-
tional dimerization of Nef from the membrane-bound
and cytosolic fractions with the immunoprecipitation
assay. Nef oligomers were demonstrated in both of these
two compartments with the fraction of oligomeric Nef
approximately two-fold higher in the membrane com-
partment. The immunoprecipitation assay should reflect
the in vivo state of Nef except for very weakly associated
Nef that would disassociate during cell lysis and immu-
noprecipitation. We have shown that the short HF tag
does not generally interfere with Nef function though
larger tags do in some instances [31]. Importantly,
immunoprecipitation from cellular extracts would be
expected to suppress non-specific interactions including
aggregation of Nef protomers [44]. Thus, our observa-
tions are distinct from the previous observations of very
weak self-association by purified Nef from bacteria (Kd >
0.5 mM) [10,45,46]. It is not clear that the weak associa-
tion observed in vitro is reflective of functionally signifi-
cant interactions inside cells.
The presence of Nef oligomers in the cytosol argues
that Nef oligomerization is not strongly inhibited by the
myristoylated N-terminal arm of Nef. If the binding
of the N-terminal arm of Nef to the core blocked
oligomerization, then the intramolecular nature of this
interaction would overwhelm any weak tendency to self-
association unless the N-terminal arm is dissociated
from the core by stable binding to membrane [47-49].
These considerations argue strongly that a negative reg-
ulation of Nef oligomerzation by its N-terminal segment
would result in cytosolic Nef being entirely monomeric.
Our observation that relatively high levels of dimers are
present in the cytosol demonstrates that the N-terminal
domain does not significantly regulate dimerization and
suggests that self-association of Nef is a constitutive
property of the protein [10,14,18]. In the absence of
data demonstrating sequestration of Nef oligomers to
membranes, we conclude that Nef is unlikely to be
sequentially regulated. Instead Nef appears to be in
equilibrium between monomeric and oligomeric forms.
Is oligomerization evolutionarily conserved?
We addressed the question of evolutionary conservation
of Nef oligomerization by investigating whether or not
SIVMAC239Nef oligomerized and whether SIVMAC239Nef
and SF2Nef associate. Our positive findings for both
cases demonstrate the existence of a conserved mechan-
ism of dimerization. Although the location of the dimer-
ization interface for this heterologous association is not
known, it is certainly expected that it will be within a
highly conserved region. This is in contrast to several
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variant structural bases [2,28]. From this evolutionary
perspective, conserved but mechanistically distinct activ-
ities like CD4 downregulation and MHCI downregula-
tion would then represent evolutionarily malleable
functions relative to oligomerization.
What regions of Nef interact to form multimers?
The interface or interfaces responsible for Nef oligomeri-
zation have not yet been defined. Previously proposed
dimerization interfaces within the Nef core are not suffi-
ciently conserved between SIVNefs and HIV-1Nefs to be
operative in these assays [10,11,18]. Nonetheless, our
results do suggest the Nef core as the site of Nef dimeri-
zation interfaces. The Nef core exhibits the highest level
of identity between SF2Nef and SIVMAC239Nef, especially
the region largely encoded by nucleotides of the polypur-
ine tract (amino acids, 88-99, in HIV-1Nef with 11 out of
12 identical). Also, our finding that dimer formation by
the SF2Nef core is strong relative to the NA7Nef core
further supports this conclusion (Figure 5B).
It does not seem likely that either the N-terminal arm
of Nef or the internal flexible loop of Nef are involved
in dimerization as they are weakly conserved between
HIV-1Nef and SIVNef. The myristoylated N-terminal
Nef synthetic peptide (amino acids 2-57) does not
dimerize [45], and we have observed dimerization of
SF2NefΔ160-175 despite removal of much of the inter-
nal loop (not shown). Therefore, Nef dimerization
domains appear to be located in the highly conserved
core of Nef [9]. These considerations validate the use of
Nef structures from crystals, even though the Nefs are
truncated for the N-terminal arm and flexible internal
loop.
ClusPro analysis of HIV-1Nef homodimers and the
HIV-1Nef and SIVNef heterodimers suggests a candi-
date interface for Nef dimerization. The critical residues
of this proposed interface are L100, I101, R105, R106,
I109, L112, W113, and H116. Four considerations sup-
port this interface. First, the residues are conserved,
especially R106, I109, L112, and W113. Second, D123 is
excluded from the model. Third, R105 and R106 inter-
act within a region that is highly conserved between
HIV-1Nef and SIVNef (HIV-1Nef residues 88-99).
Fourth, ClusPro models for HIV-1Nef homodimers and
HIV-1Nef/SIVNef heterodimers exhibit nearly identical
binding (Figure 8). Extensive mutational and phenotypic
analysis will be required to establish this model.
How many oligomeric forms of Nef exist?
The existence of one or more dimerization domains dis-
tinct from the aB plus flanking residues does not
exclude the presence of Nef dimers linked at this site. In
fact, Poe and Smithgall have provided evidence that
Nefs linked by this interface exists in intact cells [13].
However, our inability to demonstrate a role for the
R105-D123 interface by formaldehyde cross-linking
assays suggests that the dimer detected by Poe and
Smithgall is a quantitatively minor form of total Nef
dimers. In this regard, the biomolecular fluorescence
complementation assays employed by Poe and Smith-
gard freezes in place the conformations of Nef that
allow the molecular complementation of the N-terminal
85 amino acids of GFP to the C-terminal 153 amino
acids of GFP. Once formed, the reconstituted GFP may
block the dynamic equilibrium between Nef conformers
and result in the accumulation of a minor form [13].
Another HIV-1Nef dimer that could be a minor form is
the BM[PEG]3 cross-linked dimer. A second crystal
interface could account for this interaction in the
C-terminal region (Figure 9B, Magenta and Lilac).
Interaction between SIVNefs and HIV-1Nefs with host cell
proteins
There are minor Nef complexes that run above the
SF2Nef dimer band in SDS/PAGE following formalde-
hyde cross-linking (See Figure 5). Whether these bands
represent different forms of lysine cross-linked Nef with
an altered SDS/PAGE mobility or Nef cross-linked to a
different protein remains to be determined. However,
the situation for SIVMAC239Nef appears to be different.
Two prominent species of cross-linked SIVMAC239Nef
are evident in Figure 5A, right.T h el o w e ro ft h et w o
bands at approximately 82 kD could plausibly be a het-
erodimer of SIVMAC239-HFNef and a host cell protein.
Alternatively, the different mobilities could result from
variant lysine cross-links of SIVMAC239Nef dimers. We
favor the latter interpretation for the following reasons.
Of the various proteins shown to bind tightly to Nef
only Rac1 (211 amino acids) is approximately the cor-
rect size [29,30]. Skowronski and co-workers report that
Rac1 immunoprecipitates with NA7-HFNef and SIV-
MAC239Nef. As a result, either the tagged SF2-HFNef or
the untagged SF2Nef in a cross-linked heterodimer with
Rac-1 should migrate separately from SF2Nef dimer in
SDS/PAGE. This is not the case (Figure 5A and 5C).
Therefore, we conclude that the major Nef binding pro-
tein in intact cells is Nef.
The density of potential protein/protein interaction
domains displayed in Figure 9 suggests that Nef is cap-
able of initiating complex host cell associations in which
two host cell proteins are brought together to achieve
abnormal situations within the infected cell that are
advantageous to the virus. Two ternary complexes have
been recently reported between Nef, the cytoplasmic tail
of MHCI, and AP-1, and Nef, the cytoplasmic tail of
CD4, and AP-2 [40-42]. These interactions are proposed
to downregulate cell surface expression or MHCI and
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explaning Nef functional complexity is the possibility of
allosteric interactions [50]. Finally, Nef self-association
may create new interfaces for protein association with
each Nef contributing part of the interface. All of these
mechanisms should be considered in efforts to resolve
the complexities of Nef function made possible by the
fastest genome evolution ever described [51].
Conclusions
We have demonstrated significant levels of oligomeriza-
tion of Nef in cells. This property of Nef is conserved
between HIV-1Nef and SIVNef which strongly suggests
functional significance. We found that the R105D muta-
tion greatly reduced the fraction of dimeric Nef, but
exhibited only partial defects in MHCI downregulation
and PAK2 activation, and only a small effect on CD4
downregulation (Figure 7). For this reason, we favor the
explanation that the functional role of Nef dimerization
is a function not presently known.
Our results are contrary to a regulatory model in
which Nef is induced by membrane binding to produce
oligomers [14,15]. These models require cytosolic Nef to
be monomeric with Nef dimers residing strictly on
membranes, but we did not observe this to be the case.
We further observed that the myristoylation-defective
G2A mutation does not enhance oligomerization. For
this reason it does not appear that Nef’sa s s o c i a t i o n
with membrane and Nef dimerization are mechanisti-
cally related. Since Nef exhibits different functions in
multiple cellular compartments including the Golgi,
endosomes, plasma membrane and cytosol, it logically
f o l l o w st h a tm u l t i p l ec o n f o r m e r sa n do l i g o m e r so fN e f
would all have extensive distributions with monomers as
well as oligomers being functionally active [1]. The exis-
tence of multiple oligomeric forms could greatly expand
the activities exhibited by this small protein. Here we
found that a major contributor to one or more Nef
dimeric interfaces is the dibasic motif R105-R106. In the
future it will be important to not only consider Nef as
acting at specific cellular locations to elicit specific
derangements in host cell physiology but also as acting
in an expanded role throughout the cell.
Methods
Cell lines and culture conditions
293T cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM; Cellgro, Herndon, VA) supple-
mented with 10% fetal bovine serum (FBS; Cellgro), 100
IU/ml of penicillin, 100 μg/ml streptomycin, 2 mM glu-
tamine (Cellgro) in 10% CO2 at 37°C. CEM cells were
cultured in RPMI 1640 medium supplemented with 5%
FBS, 100 IU/ml penicillin, 100 μg/ml streptomycin, 2
mM L-glutamine, and 1 mM sodium pyruvate (Cellgro)
and were maintained at 37 °C in a humidified incubator
with 5% CO2.
Expression vectors
pCG and pCGCG expression vectors encoding two wild
type HIV-1Nefs, NA7Nef andS F 2 N e f ,a n dH F - t a g g e d
Nefs, NA7-HFNef and SF2-HFNef, were described in
R a n e ye ta l .[ 3 1 ] .p C G ,p C G C G ,a n dp C G 2 3 9 a h f( S I V -
MAC239Nef with the HF C-terminal tag) were provided
by Jacek Skowronski [29,30]. The HF tag contains the
HA epitope, YPYDVPDYA. pCG and pCGCG give equiva-
lent expression of Nef. SF2Nef oligomerization mutants
(R105D, D123R, R105D/D123R, R105A and R106A) and
cysteine mutants (C55S, C142S, C206X), myristoylation-
defective mutant G2A, and the Nef deletion mutant
Δ160-175 were constructed using a site-directed mutagen-
esis kit (Stratagene) with oligonucleotides designed for
each mutation. All mutated Nefs were confirmed by DNA
sequencing. NA7/SF2 Nef chimeras were made by cloning
the BlpI-BspEI fragment from SF2Nef (coding for amino
acids 24-200) into pCGCGNA7Nef and vice versa. SF2Nef
is four amino acids longer than the canonical 206 amino
acids. To avoid confusion the position of amino acid resi-
dues are referenced to a canonical length of 206 amino
acids [8].
Co-immunoprecipitation and Western blot analysis
Expression vectors encoding NA7Nef, NA7-HFNef,
SF2Nef, SF2-HFNef, SIVMAC239Nef, and SIVMAC239-
HFNef were transfected into 293T cells in 6-well plates
with Lipofectamine 2000 (Invitrogen, Carlsbad, CA).
C e l l sw e r ew a s h e di nc o l dp hosphate buffered saline
(PBS) then removed from the plate in 1 ml of 25 mM
Tris-HCl, pH = 7.5, 150 mM NaCl, and 5 mM EDTA
(Buffer A). Cell suspensionsw e r ed i s r u p t e db ys o n i c a -
tion (ten, 10 second bursts at power level 3.5) at 4°C.
Nuclei were removed by centrifugation at 800 Xg for 10
minutes. The low speed supernatant fraction was re-
spun at 27,000 rpm for 25 minutes in a MLA 130 fixed
angle rotor (Beckman). The high speed supernatant frac-
tion was separated from the pellet and adjusted to 1 ml
to contain 50 mM Tris, pH = 8.0, 100 mM NaCl, 25
mM NaF, 25 mM benzamidine, 20 mM b-glyceropho-
sphate, 2 mM Na3VO2, 3 mM EDTA, 10% glycerol, plus
Roche protease inhibitors (Buffer B). The buffer-adjusted
high speed supernatant sample was used to determine
total soluble Nef expression (100 μl) and for immunpre-
cipitation studies (900 μl). The pellet from the high
speed centrifugation was rinsed with 0.5 ml of Buffer A.
The membrane pellet was then re-suspended in 1 ml of
Buffer A by Dounce homogenization and spun at 27,000
rpm. The pellet was saved and solubilized in 1 ml of
Buffer B plus 0.5% IGEPAL CA-630 with a Dounce
homogenizer and respun at 27,000 rpm for 10 minutes.
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membrane pellet was used for determining total mem-
brane-bound Nef expression (100 μl) and for immuno-
precipitation studies (900 μl). With this procedure there
was no detectable contamination of soluble protein in
the membrane fraction or membrane protein in the solu-
ble fraction (Additional file 2; Figure S2, Left and Mid-
dle). The distribution of membrane-bound and soluble
SF2Nef and membrane-bound and soluble SF2NefG2A
w e r en e a r l yt h es a m ea sp r e v i o u s l yr e p o r t e dv a l u e s
(Additional file 2; Figure S2, Right). Nef proteins were
detected by Western blot analysis. Three monoclonal
antibodies were used for detection: EH1 from James
Hoxie [52], anti-SIV Nef 17.2 from the AIDS Repository,
anti-HA (Covance). Two polyclonal antibodies were used
for immunoprecipitations: sheep anti-SF2Nef [43] and
sheep anti-SIVMAC239Nef antibody (Rogers, RP, Foster, JL
and Garcia JV, unpublished.) Bands were quantitated by
scanning the autoradiograms and determining density
using ImageJ (Rasband, W.S., ImageJ, U. S. National
Institutes of Health, Bethesda, Maryland, USA, http://rsb.
info.nih.gov/ij/, 1997-2009). Density values are reported
as the ImageJ value divided by 1000 to simplify the
presentation.
Nef cross-linking by formaldehyde or 1,11-bis(maleimido)
triethylene glycol (BM[PEG]3)
For formaldehyde-mediated Nef cross-linking, expres-
sion vectors encoding wild type or Nef mutants were
transfected into 293T cells. Prior to harvest intact cells
were incubated with or without formaldehyde for 10
m i na tr o o mt e m p e r a t u r ea n dw a s h e dw i t hP B S .T h e n ,
whole cell lysates were prepared in Buffer B plus 0.5%
IGEPAL CA-630, centrifuged at 13,000 Xg for 30 min-
utes and the supernatant fraction collected. Cross-link-
ing of Nef by BM[PEG]3 (Pierce) was performed as
follows: Transfected 293T cells were lysed in Buffer B
plus 0.5% IGEPAL-630 and the lysate centrifuged. Clari-
fied lysates were incubated with or without BM[PEG]3
dissolved in DMSO for 1 h at room temperature. The
analysis of Nef cross-linking by formaldehyde (at lysine
residues) or BM[PEG]3 (at cysteine residues) was per-
formed by SDS-PAGE Western blotting.
Retrovirus vector preparation, transduction and flow
cytometry analysis
293T cells were transfected with the amphotropic
packaging vector pEQPAM and pLXSN (vector control)
or appropriate pLNefSN vectors with Lipofectamine
2000 (Invtrogen). Medium was harvested approximately
48 hours post-transfection and was filtered through a
0.45 μm filter.
A 24-well plate was coated with 40 μg/well of retro-
nectin (Takara Biomedicals, Kyoto, Japan). After 2 h at
room temperature, the retronectin was removed, 0.5 ml
2% bovine serum albumin in PBS was added for 30 min
at room temperature, and the wells were washed once
with PBS (0.5 ml). Filtrate (0.5 ml) containing ampho-
trophic vector was then added and left on the plate for
45 min at 37°C, and this procedure was repeated. CEM
cells (300,000) were transduced by the retronectin-
bound retroviral vector in 0.5 ml of complete RPMI
overnight at 37°C. An additional 0.5 ml of vector was
added the next day. On the following day, the cells were
re-suspended in a 12-well plate containing 1.5 mg/ml
G418 (Gibco) in a final volume of 2 ml. After 48 hours,
the cells were re-plated in a 6-well plate and 1 ml of
medium plus G418. Transduced cells then were
expanded into a T75 flask without G418 for subsequent
analysis.
The transduced CEM cells were labeled for analysis of
cell surface CD4 and MHC-1 levels. Cells (500,000)
were first incubated with a mouse monoclonal antibody
recognizing haplotypes A1, A11, and A26 of MHC class
1 (One Lambda, Canoga Park, CA) for 20 min on ice in
the dark, and then the cells were washed twice in 2 ml
of ice-cold PBS containing 5% FBS. Cells were then
incubated with fluorescein isothiocyanate (FITC)-labeled
goat anti-mouse IgG for 20 min on ice. Cells were
washed as indicated above and incubated for 20 min on
ice with 2 μg of mouse IgG, and washed again. Cells
were then incubated with phycoerythrin (PE)-conjugated
IgG monoclonal antibody to human CD4 (Exalpha,
Maynard, MA) for 20 min on ice. Stained cells were
washed and analyzed on a Becton Dickinson FACSCali-
bur instrument equipped with Cellquest-Pro software.
All fluorescence data were collected in log mode. CEM
cells transduced with LXSN served as the positive con-
trol for CD4 and MHCI cell surface expression. For
negative controls, mouse isotype antibody replaced anti-
MHC class I, and PE-conjugated mouse IgG (Exalpha)
replaced PE-conjugated anti-CD4.
Additional material
Additional file 1: Figure S1- Cross-reactivity of NA7-HFNef and SF2-
HFNef in Western blot analysis. (A), NA7-HFNef and SF2-HFNef were
expressed in 293T cells by transient transfection. Whole cell extracts were
prepared and subjected to SDS/PAGE. Three separate Western blots were
prepared and Nef detected with three separate antibodies. Lanes 1-3,
Vector control, NA7-HFNef, and SF2-HFNef, respectively. Left, Blot was
probed with monoclonal antibody EH1 (α-NefEH1). This antibody binds to
the thirteen C-terminal amino acids of SF2Nef (52). Since the last 18
amino acids of SF2Nef and NA7Nef are identical it is expected that the
interaction between these two proteins and EH1 would be identical.
Middle, blot probed with sheep anti-Nef (sheep α-Nef) Right, Blot probed
with monoclonal anti-HA (α-HA). (B), Quantitation of the Nef bands was
performed with ImageJ and the ratio of NA7-HFNef density to SF2-HFNef
density was determined for each antibody. Note that α-HA and α-NefEH1
by virtue of recognizing identical epitopes allow calculation of the
relative levels of expression of the two Nefs while the ratio of NA7-HFNef
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any difference in the ability of the sheep anti-Nef polyclonal antibody to
detect the two Nefs. The ratio of the densities for NA7-HFNef/SF2-HFNef
was determined to be 0.69 for sheep anti-Nef. The ratios for monoclonal
EH1 and anti-HA were 0.86 and 0.75, respectively giving an average of
0.805 (NA7Nef/SF2Nef). Dividing the NA7Nef/SF2Nef ratio for sheep anti-
Nef (0.69) by the estimated difference in expression between NA7-HFNef
and SF2-HFNef (0.805) in this transfection gives the fractional binding of
sheep anti-Nef to NA7Nef relative to SF2Nef which is 0.86. In other
words a 14% reduction in binding is observed for sheep anti-Nef for
NA7Nef relative to SF2Nef. The dominant epitopes for this polyclonal
antibody reside between SF2Nef amino acids 17-110 (54). NA7Nef and
SF2Nef have only 9 differences within this region (not shown).
Additional file 2: Figure S2- Distribution of SF2Nef and SF2G2A in
membrane and cytosolic compartments. 293T cells were transfected
with pCGSF2Nef and pCGSF2NefG2A. Cells that were not transfected
served as the negative control. The three cell samples were processed
for membrane and soluble fractions as described in Methods. The final
fractions were adjusted to contain total membrane protein (330 ± 60 μg,
average of three samples) and soluble protein (860 ± 130 μg, average of
three samples) each in a total volume of 1 ml. Equal aliquots of the two
fractions from each sample were analyzed by SDS/PAGE. Left- Lanes 1-3,
Soluble fractions; Lanes 4-6, Membrane fractions. Lanes 1 and 4, pCGSF2-
HFNef; Lanes 2 and 5, pCGSF2-HFNefG2A; Lanes 3 and 6, not transfected.
Western blot analysis performed with antibody to the strictly membrane
associated cadherins (α-Pan Cadherin). Middle- same as Left except
Western blot analysis performed with antibody to the strictly soluble
GAPDH (α-GAPDH). Right- same as Left except Western blot with
antibody to Nef (α-Nef). Quantification by ImageJ determined that
membrane-bound SF2-HFNef was 34% and soluble SF2-HFNef was 66%
of total Nef. Membrane-bound and soluble SF2-HFNefG2A was 8% and
92%, respectively. These values are consistent with previously reported
values for NL4-3Nef and NL4-3NefG2A in HeLa cells (16).
Additional file 3: Figure S3- Oxidation of Nef in extra-cellular
extracts. To confirm previously published results we subjected
solubilized whole cell extracts containing SF2Nef, NA7Nef, or
SIVMAC239Nef to oxidizing conditions. Extracts were prepared as described
in Methods for immunoprecipitation without β-mercaptoethanol.
Following sonication the samples were not fractionated but instead
detergent containing buffer added to give solubilized whole cell extracts
followed by centrifugation. Supernatant samples were prepared for SDS/
PAGE by boiling in SDS sample buffer with (+) and without (-) β-
mercaptoethanol. Western blots were then developed with either anti-
HIV-1Nef (α-HIVNef) or anti-SIVNef (α-SIVNef). Lanes 1, 4, 7, and 10 are
SF2Nef; Lanes 2, 5, 8, and 11 are NA7Nef; Lanes 3, 6, 9, and 12 are
SIVMAC239Nef. Lanes 1-3 and 7-9 are samples boiled in SDS sample buffer
with β-mercaptoethanol; Lanes 4-6 and 10-12 are samples boiled in SDS
sample buffer without β-mercaptoethanol.
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